Korean J Androl.  2010 Apr;28(1):9-15.

Selective Serotonin Reuptake Inhibitors for the Treatment of Premature Ejaculation

• Han CS

Abstract

Premature ejaculation (PE) affects the 20~30% men among general population regardless of their age. PE may be classified as lifelong (primary) or acquired (secondary) type. Diagnosis of PE is mainly based on subjective complaints of sexual symptoms. Recently proposed diagnostic system of PE is based on many aspects; intravaginal ejaculatory latency time (IELT), control over ejaculation, stress and interpersonal difficulty according to the PE problem. Standard treatment of lifelong PE is mainly pharmacotherapy. Among many treatment options, selective serotonin reuptake inhibitors (SSRIs) are recommended for off-label use by American Urologic Association and International Consultation on Sexual Medicine. SSRIs were reported to improve the PE symptom by lengthening IELT. However, daily intake of SSRIs often increases the possibility of adverse effects, such as nausea, diarrhea, loss of libido, and even erectile dysfunction. Recently, dapoxetine hydrochloride, newer SSRI with short half life, was tailored to target the PE. Dapoxetine was proved its efficacy on PE over placebo. Clinicians should keep in mind that the sexual dysfunction can be the primary complaints or the results of the intake of antidepressants at the same time.

Keyword

Premature Ejaculation; Antidepressant; Selective Serotonin Reuptake Inhibitor

MeSH Terms

Antidepressive Agents
Benzylamines
Diarrhea
Ejaculation
Erectile Dysfunction
Half-Life
Humans
Libido
Male
Naphthalenes
Nausea
Off-Label Use
Premature Ejaculation
Serotonin Uptake Inhibitors
Antidepressive Agents
Benzylamines
Naphthalenes
Serotonin Uptake Inhibitors